Study Comparing Isolated Pelvic Perfusion With TNF-α 0.3 mg and Melphalan 1.5 mg/kg Versus Standard Treatment in Patients With Non Resectable, Recurrent Gynaecologic or Digestive Pelvic Cancer

Inclusion Criteria: * Histologically proved locally advanced gynaecologic or digestive tumours (epidermoid carcinomas, adenocarcinomas, neuroendocrine tumours, sarcomas or melanomas), (cervix, vagina, rectal, anal). * Locally recurrent tumours for which surgical treatment will be mutilating or marginal (R1 or R2) and/or for cervix cancer, primary tumours non accessible for standard treatment (radiotherapy- chemotherapy - brachytherapy and surgery). * Surgically resectable tumour (R0 type) but for which patient does not agree with surgery. * Patients aged over 18 and under 76 ans * Performance OMS Index ≤ 2 * Normal biologic parameters * Good general and cardiac state (ASA I or II and NYHA I or II) Exclusion Criteria: * Surgically resectable tumour (RO) or peritoneal tumour extension or distant metastasis. * Cardiac or vascular pathology * Pulmonary disease * Uncontrolled Sepsis disease * Pregnancy